Microneedle-mediated transdermal delivery of nanostructured lipid carriers for alkaloids from Aconitum sinomontanum
Source abstract
Abstract
A combination method using microneedle (MN) pretreatment and nanostructured lipid carriers (NLCs) was developed to improve the transdermal delivery of therapeutics. The MN treatment of the skin and co-administration of NLCs loaded with total alkaloids isolated from Aconitum sinomontanum (AAS-NLCs) significantly increased the skin permeation of the drugs. Fluorescence imaging confirmed that MNs could provide microchannels penetrating the stratum corneum, and delivery of NLCs through the channels led to their deeper permeation. In vivo studies showed that combination of AAS-NLCs with MNs (AAS-NLCs-MN) in transdermal delivery could improve the bioavailability and maintain stable drug concentrations in the blood. Moreover, AAS-NLCs-MN showed benefits in eliminating paw swelling, decreasing inflammation and pain, and regulating immune function in adjuvant arthritis rats. After administration of AAS-NLCs-MN, no skin irritation was observed in rabbits, and electrocardiograms of rats showed improved arrhythmia. These results indicated that the dual approach combining MN insertion and NLCs has the potential to provide safe transdermal delivery and to improve the therapeutic efficacy through sustained release of AAS.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Plant-based Medicinal Research · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China
Funding
State Education Ministry of China · the National Natural Science Foundation of China
References (31)
Show source-provided references
1. 10.1016/j.jconrel.2017.05.02910.1016/j.jconrel.2017.05.029 ↗
2. 10.1016/j.jconrel.2008.04.01910.1016/j.jconrel.2008.04.019 ↗
3. 10.1080/21691401.2017.136633610.1080/21691401.2017.1366336 ↗
4. 10.1016/j.ejpb.2013.12.00410.1016/j.ejpb.2013.12.004 ↗
5. 10.1016/j.ejpb.2017.04.00810.1016/j.ejpb.2017.04.008 ↗
6. 10.3109/21691401.2016.116769910.3109/21691401.2016.1167699 ↗
7. Yuan CL · Nat Prod Res · 2012 · 26 · 2099
8. 10.1186/s12951-015-0107-310.1186/s12951-015-0107-3 ↗
9. 10.1016/j.ejpb.2011.03.02110.1016/j.ejpb.2011.03.021 ↗
10. 10.1016/j.ejpb.2013.01.02610.1016/j.ejpb.2013.01.026 ↗
11. 10.1248/bpb.b13-0005010.1248/bpb.b13-00050 ↗
12. 10.1016/j.ijpharm.2010.09.03710.1016/j.ijpharm.2010.09.037 ↗
13. 10.1111/jphp.1211810.1111/jphp.12118 ↗
14. 10.1166/jbn.2015.190210.1166/jbn.2015.1902 ↗
15. 10.1016/j.ijpharm.2017.04.03210.1016/j.ijpharm.2017.04.032 ↗
16. 10.1016/j.phymed.2014.02.00310.1016/j.phymed.2014.02.003 ↗
17. 10.3109/21691401.2013.83268310.3109/21691401.2013.832683 ↗
18. Lee SG · Int J Nanomed · 2014 · 9 · 289
19. 10.3109/21691401.2016.113848610.3109/21691401.2016.1138486 ↗
20. 10.1016/j.ejpb.2006.10.01910.1016/j.ejpb.2006.10.019 ↗
21. 10.1111/j.2042-7158.2012.01557.x10.1111/j.2042-7158.2012.01557.x ↗
22. Wang Q · Yao Xue Xue Bao · 2011 · 46 · 432
23. 10.1016/j.ijpharm.2005.01.00410.1016/j.ijpharm.2005.01.004 ↗
24. 10.1007/s11095-010-0191-x10.1007/s11095-010-0191-x ↗
25. 10.1038/s41598-017-03759-w10.1038/s41598-017-03759-w ↗
26. 10.1016/j.biopha.2017.05.05510.1016/j.biopha.2017.05.055 ↗
27. 10.1016/S0254-6272(14)60060-110.1016/S0254-6272(14)60060-1 ↗
28. 10.1073/pnas.86.22.903010.1073/pnas.86.22.9030 ↗
29. 10.1371/journal.pone.014640010.1371/journal.pone.0146400 ↗
30. Guo X · Acta Pharmacol Sin · 1989 · 10 · 504
31. 10.1093/toxsci/kfr02110.1093/toxsci/kfr021 ↗